Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205
| Autor: | Li, T. *, Christos, P.J., Sparano, J.A., Hershman, D.L., Hoschander, S., O’Brien, K., Wright, J.J., Vahdat, L.T. |
|---|---|
| Zdroj: | In Annals of Oncology April 2009 20(4):642-647 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|